Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 - 1965

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Cartwright, Emily J ^a   Rentsch, Christopher ^b   Rimland, David ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Prevention control; Screening

Indexed keywords

HEPATITIS C ANTIBODY;

AGED; BLOOD; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; RISK; RISK FACTOR; UNITED STATES; VETERAN;

AGED; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PREVALENCE; RISK FACTORS; UNITED STATES; VETERANS;

EID: 84904087154     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-449     Document Type: Article

References (31)

1. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention, MMWR 1998 47 No. RR-19 1 39
2. Public health service inter-agency guidelines for screening donors of blood, plasma, organs, tissue, and semen for evidence of hepatitis B and hepatitis C. Centers for Disease Control and Prevention, MMWR 1991 40 RR-4 1 17
3. Hepatitis C testing and prevention counseling guidelines for VA health care practitioners. http://www.hepatitis.va.gov/
4. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N, Alter M, Yartel A, Ward JW, MMWR Recomm Rep 2012 61 RR-4 1 32
5. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. Southern WN, Drainoni ML, Smith BD, Christiansen CL, McKee D, Gifford AL, Weinbaum CM, Thompson D, Koppelman E, Maher S, Litwin AH, J Viral Hepat 2011 18 7 474 481
6. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM, Ann Intern Med 2013 158 2 101 108
7. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. Backus LI, Belperio PS, Loomis TP, Yip GH, Mole LA, JAMA Intern Med 2013 173 16 1549 1552
8. Examining hepatitis C virus testing practices in primary care clinics. Almario CV, Vega M, Trooskin SB, Navarro VJ, J Viral Hepat 2012 19 2 163 e169
9. Population-based hepatitis C surveillance and treatment in a national managed care organization. Shatin D, Schech SD, Patel K, McHutchison JG, Am J Manag Care 2004 10 4 250 256 (Pubitemid 38480794)
10. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, Christiansen CL, Weinbaum CM, Southern WN, Dig Liver Dis 2012 44 6 497 503
11. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Briggs ME, Baker C, Hall R, Gaziano JM, Gagnon D, Bzowej N, Wright TL, Hepatology 2001 34 6 1200 1205 (Pubitemid 33096593)
12. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Brau N, Bini EJ, Shahidi A, Aytaman A, Xiao P, Stancic S, Eng R, Brown ST, Paronetto F, Am J Gastroenterol 2002 97 8 2071 2078
13. Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest. Sloan KL, Straits-Troster KA, Dominitz JA, Kivlahan DR, J Clin Gastroenterol 2004 38 3 279 284 (Pubitemid 38233339)
14. Epidemiology of hepatitis C virus infection in American veterans. Cheung RC, Am J Gastroenterol 2000 95 3 740 747 (Pubitemid 30123913)
15. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ, Ann Intern Med 2006 144 10 705 714 (Pubitemid 46780630)
16. Injection drug users in the United States, 1979-2002: an aging population. Armstrong GL, Arch Intern Med 2007 167 2 166 173 (Pubitemid 46148064)
17. Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index. Murphy EL, Fang J, Tu Y, Cable R, Hillyer CD, Sacher R, Triulzi D, Gottschall JL, Busch MP, J Infect Dis 2010 202 4 576 584
18. Estimating the number of injecting drug users in Scotland's HCV diagnosed population using capture-recapture methods. McDonald SA, Hutchinson SJ, Schnier C, McLeod A, Goldberg DJ, Epidemiol Infect 2014 142 1 200 207
19. The prevalence of hepatitis C in England and Wales. Balogun MA, Ramsay ME, Hesketh LM, Andrews N, Osborne KP, Gay NJ, Morgan-Capner P, J Infect 2002 45 4 219 226 (Pubitemid 36104853)
20. Hepatitis C virus infection in cameroon: a cohort-effect. Nerrienet E, Pouillot R, Lachenal G, Njouom R, Mfoupouendoun J, Bilong C, Mauclere P, Pasquier C, Ayouba A, J Med Virol 2005 76 2 208 214 (Pubitemid 40594005)
21. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, Tobler L, Andrews W, Avanesyan L, Cooper S, Busch MP, J Infect Dis 2009 200 8 1216 1226
22. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, Shaw-Stiffel T, Weston SJ, Thiede H, Wald A, Rosen HR, J Infect Dis 2007 196 10 1474 1482 (Pubitemid 351411983)
23. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. van der Berg CH, Grady BP, Schinkel J, van de Laar T, Molenkamp R, van Houdt R, Coutinho RA, van Baarle D, Prins M, Plos One 2011 6 11 27555
24. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M, Hepatology 2014 59 109 120
25. Vital signs: evaluation of hepatitis C virus infection testing and reporting-eight U.S. sites, 2005-2011. MMWR Morb Mortal Wkly Rep 2013 62 18 357 361
26. Testing for HCV infection: an update of guidance for clinicians and laboratorians. Centers for Disease Control and Prevention, MMWR 2013 62 18 357 361
27. Current and future therapies for hepatitis C virus infection. Liang TJ, Ghany MG, N Engl J Med 2013 368 20 1907 1917
28. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL, Ann Intern Med 2007 147 10 677 684 (Pubitemid 351664462)
29. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P, J Hepatol 2010 52 5 652 657
30. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL, JAMA 2012 308 24 2584 2593
31. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS, Hepatology 2010 52 3 833 844